• Givefront

  Participated · Seed · Dec 2025

  Givefront is building a unified financial platform tailored to the 1.9 million registered nonprofits in the United States, including food banks, churches, animal rescues, NGOs, and homeowner associations. The software layers real-time spend controls, grant-based budgeting, receipt capture, and automated reporting on top of legacy accounting systems such as Blackbaud and Sage to meet nonprofits’ stringent compliance demands. After realizing that replacing entire accounting stacks was a lengthy sales cycle, the founders pivoted to a card-first spend-management approach, allowing organizations to adopt Givefront simply by switching their payment card. The company earns revenue from card interchange and subscriptions attached to its bill-pay feature, and reports more than 200% month-over-month growth in both revenue and total payment volume since launching its cards six months ago. Hundreds of organizations have already onboarded, with a target of serving about 1,000 nonprofits by year-end and 5,000 by mid-next year; churches and religious groups currently lead adoption. Future product extensions include payroll, banking, budgeting, and potential investment and endowment management modules. Givefront was founded by 21-year-olds Matt Tengtrakool and Aidan Sunbury, alongside a 17-year-old founding engineer, drawing on Tengtrakool’s first-hand experience running student nonprofits.

• TômTex Co

  Participated · Seed · Apr 2022

  TômTex is a New York-based sustainable biomaterial producer that makes biodegradable textiles from chitosan, a biopolymer sourced from seafood shells and mushrooms. Its material has been used by designers and brands including Peter Do, Di Petsa, Dauphinette and Maitrepierre at New York and Paris Fashion Weeks. The textile can be custom-moulded, stamped, 3D-printed or embossed in animal leather-style patterns. The company recently achieved a production milestone of 100 linear feet in its initial run and plans to scale to larger-scale production. Founder Uyen Tran said the $2.25M seed will fund team growth, key hires and expanded manufacturing and help secure new contracts and revenue. With this round TômTex has raised $4.15M to date, including a prior $1.9M round. Investors including Happiness Capital, SOSV, Parley for the Oceans, MIH Capital and Earth Venture Capital have expressed support for the company's technology and environmental potential. TômTex produces a biodegradable leather alternative made from chitosan derived from shell seafood and mushroom waste. The material is designed to mimic leather’s look and feel while avoiding petrochemical "vegan leather" and reducing environmental harm. The company is targeting the $400 billion global leather market and is initially focusing on luxury leather goods, developing partnerships with large brands and designers in New York City. TômTex plans to expand beyond luxury goods into apparel and accessories and later into consumer electronics and automotive interior applications as it advances material properties. The startup will use its $1.7M pre-seed funding to bring the product to market and to grow its team beyond the three founders, hiring business development, technical staff, a senior scientist, and marketing/communications. Headquartered in New York City, TômTex emphasizes circularity by using waste-derived feedstocks and water- or ethanol-based processing to avoid harsh chemistries and improve biodegradability.

• VenoStent

  Participated · Seed · Feb 2021

  VenoStent is a Houston, TX–based clinical-stage medical device company developing SelfWrap, a bioabsorbable perivascular wrap placed around arteriovenous access sites during fistula-creation surgery. The wrap is intended to accelerate usability and increase the durability of AV fistula sites for chronic kidney disease patients requiring hemodialysis by mimicking the arterial environment in veins and leveraging the body’s healing mechanisms. The company is led by CEO Tim Boire, Ph.D., and COO Geoffrey Lucks. VenoStent recently completed its Series A financing at $20M, including a $4M investment from Norwest Venture Partners. It was also awarded a $3.6M SBIR Phase II grant from the NIH to help fund a planned multi-center, 200-patient randomized controlled trial in the U.S. The company intends to use the funds to support clinical development and the RCT to validate SelfWrap's impact on fistula usability and durability. VenoStent is a clinical-stage, venture-backed therapeutic medical device company developing a bioabsorbable wrap, SelfWrap, to transform outcomes in vascular surgery, starting with hemodialysis access. SelfWrap is intended to improve the usability and durability of arteriovenous fistulas (AVFs) used by chronic kidney disease patients for dialysis. The company recently closed a $16M Series A financing to support clinical and manufacturing work. VenoStent plans to use the funds to expand its US pivotal trial and scale manufacturing capabilities as it pursues FDA approval. The company has been granted an Investigational Device Exemption (IDE) from the FDA for its US clinical trial, SAVE-FistulaS. VenoStent is led by CEO Tim Boire, Ph.D., and has previously received funding from KidneyX, the National Science Foundation, the National Institutes of Health, Y Combinator, Health Wildcatters, and Texas Halo Fund. VenoStent’s core technology is polymer engineering protected by patents; its first product, SelfWrap, is a slip-on bioresorbable wrap intended to address the 55–65% vascular access surgery failure rate in hemodialysis patients. The company aims to complete first-in-human clinical work and conduct studies to support Breakthrough Device Designation (BDD) and an Investigational Device Exemption (IDE) submission. Proceeds from the recent round will be used to grow the team, scale quality control and manufacturing processes, and strengthen clinical and reimbursement positions. VenoStent has participated in Y Combinator’s Summer 2020 batch and is led by Co-Founder and CEO Tim Boire, Ph.D., with Geoff Lucks as Co-Founder and COO. Its funding to date exceeds $6M, which includes non-dilutive grants and prize awards alongside prior equity investments.

No current team members are available.